Tissue-Selective Estrogen Complex May Benefit Postmenopausal Women With Vaginal Bleeding, Breast DiscomfortNovember 09, 2018
Switching to tissue-selective estrogen complex from hormone therapy may benefit women with breast discomfort or vaginal bleeding.
Approval from the Food and Drug Administration (FDA) was supported by the Phase 3 Replenish trial which evaluated the safety and efficacy of Bijuva in generally healthy, postmenopausal women with a uterus for the treatment of moderate to severe hot flashes.
Compared with women who experience normal or late menopause, women who experience early natural menopause have a shorter life expectancy and spend fewer years without type 2 diabetes.
Higher levels of estradiol were inversely associated with carotid artery intima-media thickness progression in the early postmenopausal cohort but positively associated with it in the late postmenopausal group.
Postmenopausal women with weight loss have a reduced risk for breast cancer.
Hypertensive disorders of pregnancy and gestational diabetes may increase the risk for hot flashes during menopause.
Light treatments successfully corrected abnormal timing of melatonin circadian rhythms in perimenopausal women with depression and improved mood and sleep within 2 weeks.
Researchers concluded that physical activity was not associated with risk for early menopause.
According to the Imvexxy prescribing information, women should generally be started at the 4mcg dosage strength with dosage adjustment guided by clinical response.
The 5 topics addressed by the 11-member expert panel include epidemiology, clinical presentation, therapeutic effects of antidepressants, effects of hormone therapy, and the effectiveness of other therapies (eg, psychotherapy, exercise, natural health products).
Stroke risk 19% lower with breastfeeding for 1 to 6 months; stronger link for longer duration.
The International Society for the Study of Women's Sexual Health convened an expert consensus panel to discuss the use of androgens in the management of genitourinary syndrome of menopause.
Investigators examined the relationship between menstrual cycle characteristics in adolescence and early adulthood and the risk for early natural menopause.
No Impact on Carotid Artery Intima-Media Thickness Following Cessation of Menopausal Hormone TherapyAugust 13, 2018
A follow-up study from KEEPS found that cessation of menopausal hormone therapy did not change the expected trajectory of carotid artery intima-media thickness over a 3-year period.
The insulin sensitivity in post- and premenopausal women along with lipid deposition in the liver and skeletal muscle was examined.
This retrospective study sought to assess migraine patterns in 69 menopausal women between ages 40 and 60 who were treated at Partners Healthcare Hospitals for concurrent migraine headache.
Women prescribed long- vs short-term opioids for chronic musculoskeletal pain may be at increased risk for menopause and abnormal menstruation.
Hormone therapy in postmenopausal women with mild cognitive impairment was examined.
No Additional Benefits With Vaginal Estradiol Tablets, Moisturizers for Postmenopausal Vulvovaginal SymptomsJune 14, 2018
Prescribed vaginal estradiol tablets and over-the-counter vaginal moisturizers may not be more effective than placebos for postmenopausal vulvovaginal symptoms.
Equol-containing nutraceuticals may be beneficial for postmenopausal women with vaginal symptoms.
The FDA approval was supported by findings from a Phase 3, randomized, double-blind, placebo-controlled study that evaluated Imvexxy (4mcg and 10mcg) vs placebo from baseline to week 12.
The two most prevalent HIV symptoms, fatigue and muscle aches, are more common in women than men and can worsen with menopause.
UTIs present clinically as dysuria, with symptoms of frequent and urgent urination secondary to irritation of the urethral and bladder mucosa.
Body mass index BMI at a cut-point of 30 kg/m2 may not be an appropriate indicator of obesity in postmenopausal women.
The USPSTF has updated its recommendations on the use of menopausal hormone therapy for the primary prevention of chronic conditions.
Early menopause risk is highest in weight-cycling and severely underweight women.
The researchers found no long-term increase in either all-cause or cause-specific mortality among women who received hormone therapy for up to 5.6 years or 7.2 years, depending on the type of therapy.
Women who experienced early menopause were 2.4 times more likely to develop diabetes.
Intrarosa provides an additional treatment option for women with dyspareunia caused by vulvar and vaginal atrophy.
Women may have a higher risk of type 2 diabetes with low levels of sex hormone-binding globulin and high levels of total estradiol.